- Home
- FCO vs AVTX Comparison
FCO vs AVTX Comparison
Compare FCO & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- AVTX
- Stock Information
- Founded
- FCO 1991
- AVTX 2011
- Country
- FCO United Kingdom
- AVTX United States
- Employees
- FCO N/A
- AVTX N/A
- Industry
- FCO Investment Managers
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- FCO Finance
- AVTX Health Care
- Exchange
- FCO Nasdaq
- AVTX Nasdaq
- Market Cap
- FCO 80.3M
- AVTX 88.4M
- IPO Year
- FCO N/A
- AVTX 2015
- Fundamental
- Price
- FCO $5.98
- AVTX $8.44
- Analyst Decision
- FCO
- AVTX Strong Buy
- Analyst Count
- FCO 0
- AVTX 4
- Target Price
- FCO N/A
- AVTX $33.00
- AVG Volume (30 Days)
- FCO 100.1K
- AVTX 36.6K
- Earning Date
- FCO 01-01-0001
- AVTX 03-28-2025
- Dividend Yield
- FCO 14.96%
- AVTX N/A
- EPS Growth
- FCO N/A
- AVTX N/A
- EPS
- FCO 0.43
- AVTX N/A
- Revenue
- FCO N/A
- AVTX $820,000.00
- Revenue This Year
- FCO N/A
- AVTX N/A
- Revenue Next Year
- FCO N/A
- AVTX N/A
- P/E Ratio
- FCO $12.30
- AVTX N/A
- Revenue Growth
- FCO N/A
- AVTX N/A
- 52 Week Low
- FCO $4.73
- AVTX $4.24
- 52 Week High
- FCO $6.63
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- FCO 46.51
- AVTX 57.77
- Support Level
- FCO $5.92
- AVTX $6.81
- Resistance Level
- FCO $6.12
- AVTX $8.00
- Average True Range (ATR)
- FCO 0.10
- AVTX 0.56
- MACD
- FCO -0.01
- AVTX 0.03
- Stochastic Oscillator
- FCO 17.65
- AVTX 81.99
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).